Editorial updates
Dated editorial updates on peptide regulation, research, and access. Each entry follows the same sourcing standard as our reference pages and links out to the peptide guides it references.
editorial, science, market
The cultural conversation collapses three different things into one word. Pulling them apart is the most useful editorial work this site does — and it's the difference between a $1.4B FDA-approved drug and a substance with no human safety data.
international, regulatory, access
A wellness-travel category that didn't exist as a category five years ago has become a fixture of TikTok and a recurring story in mainstream press. The map of where it actually works — and where it carries real risk — is more constrained than the social posts suggest.
regulatory, compounding, safety
'Compounded' is not a single category. The safety question depends on whether the substance is on a 503A or 503B bulks list, on the pharmacy's track record, and on what the clinician documents — not on marketing language.
regulatory, compounding, shortage list, GLP-1
FDA declared the tirzepatide injection shortage resolved in December 2024. The compounded-tirzepatide landscape changed materially over the following year — but the regulatory geometry is more nuanced than 'compounding is now banned.'
regulatory, compounding, FDA
FDA's April 22, 2026 503A bulks-list update reshuffled the compounded-peptide landscape. Here's what moved, what stayed, and what each change actually means.
